Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer.

Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M.

Prostate. 2019 Oct 15. doi: 10.1002/pros.23919. [Epub ahead of print]

PMID:
31614001
2.

Breast MRI in the era of diffusion weighted imaging: do we still need signal-intensity time curves?

Dietzel M, Ellmann S, Schulz-Wendtland R, Clauser P, Wenkel E, Uder M, Baltzer PAT.

Eur Radiol. 2019 Jul 29. doi: 10.1007/s00330-019-06346-x. [Epub ahead of print]

PMID:
31359125
3.

Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis.

Janisch F, Shariat SF, Baltzer P, Fajkovic H, Kimura S, Iwata T, Korn P, Yang L, Glybochko PV, Rink M, Abufaraj M.

World J Urol. 2019 Jul 18. doi: 10.1007/s00345-019-02875-8. [Epub ahead of print]

PMID:
31321509
4.

Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy.

Abufaraj M, Grubmüller B, Zeitlinger M, Kramer G, Seitz C, Haitel A, Baltzer P, Hacker M, Wadsak W, Pfaff S, Wiatr T, Mitterhauser M, Shariat SF, Hartenbach M.

Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2169-2177. doi: 10.1007/s00259-019-04361-0. Epub 2019 Jun 29.

5.

Multiparametric 18F-FDG PET-MRI of the breast: are there differences in imaging biomarkers of contralateral healthy tissue between patients with and without breast cancer?

Leithner D, Helbich TH, Bernard-Davila B, Marino MA, Avendano D, Martinez DF, Jochelson M, Kapetas P, Baltzer PA, Haug A, Hacker M, Tanyildizi Y, Morris EA, Pinker K.

J Nucl Med. 2019 Jun 28. pii: jnumed.119.230003. doi: 10.2967/jnumed.119.230003. [Epub ahead of print]

PMID:
31253745
6.

Stent-graft surface movement after endovascular aneurysm repair: baseline parameters for prediction, and association with migration and stent-graft-related endoleaks.

Asenbaum U, Schoder M, Schwartz E, Langs G, Baltzer P, Wolf F, Prusa AM, Loewe C, Nolz R.

Eur Radiol. 2019 Jun 27. doi: 10.1007/s00330-019-06282-w. [Epub ahead of print]

PMID:
31250169
7.

A multiparametric [18F]FDG PET/MRI diagnostic model including imaging biomarkers of the tumor and contralateral healthy breast tissue aids breast cancer diagnosis.

Leithner D, Horvat JV, Bernard-Davila B, Helbich TH, Ochoa-Albiztegui RE, Martinez DF, Zhang M, Thakur SB, Wengert GJ, Staudenherz A, Jochelson MS, Morris EA, Baltzer PAT, Clauser P, Kapetas P, Pinker K.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1878-1888. doi: 10.1007/s00259-019-04331-6. Epub 2019 Jun 13.

8.

Application of Baseline Clinical and Morphological Parameters for Prediction of Late Stent Graft Related Endoleaks after Endovascular Repair of Abdominal Aortic Aneurysm.

Nolz R, Schoder M, Baltzer P, Prusa A, Javor D, Loewe C, Asenbaum U.

Eur J Vasc Endovasc Surg. 2019 Jul;58(1):24-32. doi: 10.1016/j.ejvs.2018.11.002. Epub 2019 May 31.

PMID:
31160189
9.

Intra- and inter-observer variability in dependence of T1-time correction for common dynamic contrast enhanced MRI parameters in prostate cancer patients.

Daniel M, Polanec SH, Wengert G, Clauser P, Pinker K, Helbich TH, Georg D, Baltzer PAT.

Eur J Radiol. 2019 Jul;116:27-33. doi: 10.1016/j.ejrad.2019.04.015. Epub 2019 Apr 23.

PMID:
31153570
10.

Correction to: Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

Rageth CJ, O'Flynn EAM, Pinker K, Kubik-Huch RA, Mundinger A, Decker T, Tausch C, Dammann F, Baltzer PA, Fallenberg EM, Foschini MP, Dellas S, Knauer M, Malhaire C, Sonnenschein M, Boos A, Morris E, Varga Z.

Breast Cancer Res Treat. 2019 Jul;176(2):481-482. doi: 10.1007/s10549-019-05287-9.

11.

Diffusion-Weighted MRI of Breast Cancer: Improved Lesion Visibility and Image Quality Using Synthetic b-Values.

Bickel H, Polanec SH, Wengert G, Pinker K, Bogner W, Helbich TH, Baltzer PA.

J Magn Reson Imaging. 2019 May 28. doi: 10.1002/jmri.26809. [Epub ahead of print]

PMID:
31136044
12.

[Contrast-agent free imaging of the prostate : Ready for clinical practice?]

Polanec SH, Bickel HS, Baltzer PAT.

Radiologe. 2019 Jun;59(6):503-509. doi: 10.1007/s00117-019-0531-8. Review. German.

PMID:
31037321
13.

Does higher field strength translate into better diagnostic accuracy? A prospective comparison of breast MRI at 3 and 1.5 Tesla.

Dietzel M, Wenkel E, Hammon M, Clauser P, Uder M, Schulz-Wendtland R, Baltzer PAT.

Eur J Radiol. 2019 May;114:51-56. doi: 10.1016/j.ejrad.2019.02.033. Epub 2019 Feb 28.

PMID:
31005176
14.

[Contrast agent-free breast MRI : Advantages and potential disadvantages].

Baltzer PAT, Kapetas P, Sodano C, Dietzel M, Pinker K, Helbich TH, Clauser P.

Radiologe. 2019 Jun;59(6):510-516. doi: 10.1007/s00117-019-0524-7. Review. German.

PMID:
31001650
15.

Can we predict lesion detection rates in second-look ultrasound of MRI-detected breast lesions? A systematic analysis.

Bumberger A, Clauser P, Kolta M, Kapetas P, Bernathova M, Helbich TH, Pinker K, Baltzer PA.

Eur J Radiol. 2019 Apr;113:96-100. doi: 10.1016/j.ejrad.2019.02.008. Epub 2019 Feb 11.

PMID:
30927966
16.

Diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer.

Horvat JV, Bernard-Davila B, Helbich TH, Zhang M, Morris EA, Thakur SB, Ochoa-Albiztegui RE, Leithner D, Marino MA, Baltzer PA, Clauser P, Kapetas P, Bago-Horvath Z, Pinker K.

J Magn Reson Imaging. 2019 Sep;50(3):836-846. doi: 10.1002/jmri.26697. Epub 2019 Feb 27.

17.

Sequential [18F]FDG-[18F]FMISO PET and Multiparametric MRI at 3T for Insights into Breast Cancer Heterogeneity and Correlation with Patient Outcomes: First Clinical Experience.

Andrzejewski P, Wengert G, Helbich TH, Magometschnigg H, Georg D, Hacker M, Baltzer P, Clauser P, Kapetas P, Georg P, Wadsak W, Pinker K.

Contrast Media Mol Imaging. 2019 Jan 8;2019:1307247. doi: 10.1155/2019/1307247. eCollection 2019.

18.

PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT.

Magometschnigg H, Pinker K, Helbich T, Brandstetter A, Rudas M, Nakuz T, Baltzer P, Wadsak W, Hacker M, Weber M, Dubsky P, Filipits M.

Mol Imaging Biol. 2019 Oct;21(5):991-1002. doi: 10.1007/s11307-018-01308-z.

PMID:
30652258
19.

Automated Detection and Segmentation of Nonmass-Enhancing Breast Tumors with Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

Illan IA, Ramirez J, Gorriz JM, Marino MA, Avendano D, Helbich T, Baltzer P, Pinker K, Meyer-Baese A.

Contrast Media Mol Imaging. 2018 Oct 24;2018:5308517. doi: 10.1155/2018/5308517. eCollection 2018.

20.

Quantitative Multiparametric Breast Ultrasound: Application of Contrast-Enhanced Ultrasound and Elastography Leads to an Improved Differentiation of Benign and Malignant Lesions.

Kapetas P, Clauser P, Woitek R, Wengert GJ, Lazar M, Pinker K, Helbich TH, Baltzer PAT.

Invest Radiol. 2019 May;54(5):257-264. doi: 10.1097/RLI.0000000000000543.

PMID:
30632985
21.

Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder.

Stangl-Kremser J, D'Andrea D, Vartolomei M, Abufaraj M, Goldner G, Baltzer P, Shariat SF, Tamandl D.

Urol Oncol. 2019 Jun;37(6):372-379. doi: 10.1016/j.urolonc.2018.11.001. Epub 2018 Dec 18.

PMID:
30578161
22.

Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.

Grubmüller B, Senn D, Kramer G, Baltzer P, D'Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, Shariat SF, Hacker M, Hartenbach M.

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1063-1072. doi: 10.1007/s00259-018-4236-4. Epub 2018 Dec 19.

23.

Breast lesion detection and characterization with contrast-enhanced magnetic resonance imaging: Prospective randomized intraindividual comparison of gadoterate meglumine (0.15 mmol/kg) and gadobenate dimeglumine (0.075 mmol/kg) at 3T.

Clauser P, Helbich TH, Kapetas P, Pinker K, Bernathova M, Woitek R, Kaneider A, Baltzer PAT.

J Magn Reson Imaging. 2019 Apr;49(4):1157-1165. doi: 10.1002/jmri.26335. Epub 2018 Dec 15.

24.

Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

Rageth CJ, O'Flynn EAM, Pinker K, Kubik-Huch RA, Mundinger A, Decker T, Tausch C, Dammann F, Baltzer PA, Fallenberg EM, Foschini MP, Dellas S, Knauer M, Malhaire C, Sonnenschein M, Boos A, Morris E, Varga Z.

Breast Cancer Res Treat. 2019 Apr;174(2):279-296. doi: 10.1007/s10549-018-05071-1. Epub 2018 Nov 30. Review. Erratum in: Breast Cancer Res Treat. 2019 Jul;176(2):481-482.

25.

Impact of androgen deprivation therapy on apparent diffusion coefficient and T2w MRI for histogram and texture analysis with respect to focal radiotherapy of prostate cancer.

Daniel M, Kuess P, Andrzejewski P, Nyholm T, Helbich T, Polanec S, Dragschitz F, Goldner G, Georg D, Baltzer P.

Strahlenther Onkol. 2019 May;195(5):402-411. doi: 10.1007/s00066-018-1402-3. Epub 2018 Nov 26.

26.

Development of a Non-invasive Assessment of Hypoxia and Neovascularization with Magnetic Resonance Imaging in Benign and Malignant Breast Tumors: Initial Results.

Stadlbauer A, Zimmermann M, Bennani-Baiti B, Helbich TH, Baltzer P, Clauser P, Kapetas P, Bago-Horvath Z, Pinker K.

Mol Imaging Biol. 2019 Aug;21(4):758-770. doi: 10.1007/s11307-018-1298-4.

PMID:
30478507
27.

Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.

Tahmassebi A, Wengert GJ, Helbich TH, Bago-Horvath Z, Alaei S, Bartsch R, Dubsky P, Baltzer P, Clauser P, Kapetas P, Morris EA, Meyer-Baese A, Pinker K.

Invest Radiol. 2019 Feb;54(2):110-117. doi: 10.1097/RLI.0000000000000518.

PMID:
30358693
28.

[Imaging of the kidneys and the urinary tract].

Herold C, Baltzer P.

Radiologe. 2018 Oct;58(10):885-886. doi: 10.1007/s00117-018-0445-x. German. No abstract available.

PMID:
30291408
29.

Synthetic 2-Dimensional Mammography Can Replace Digital Mammography as an Adjunct to Wide-Angle Digital Breast Tomosynthesis.

Clauser P, Baltzer PAT, Kapetas P, Woitek R, Weber M, Leone F, Bernathova M, Helbich TH.

Invest Radiol. 2019 Feb;54(2):83-88. doi: 10.1097/RLI.0000000000000513.

PMID:
30281557
30.

Density and tailored breast cancer screening: practice and prediction - an overview.

Wengert GJ, Helbich TH, Kapetas P, Baltzer PA, Pinker K.

Acta Radiol Open. 2018 Sep 17;7(9):2058460118791212. doi: 10.1177/2058460118791212. eCollection 2018 Sep.

31.

Imaging Phenotypes in Women at High Risk for Breast Cancer on Mammography, Ultrasound, and Magnetic Resonance Imaging Using the Fifth Edition of the Breast Imaging Reporting and Data System.

Marino MA, Riedl CC, Bernathova M, Bernhart C, Baltzer PAT, Helbich TH, Pinker K.

Eur J Radiol. 2018 Sep;106:150-159. doi: 10.1016/j.ejrad.2018.07.026. Epub 2018 Jul 30.

PMID:
30150038
32.

PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact.

Grubmüller B, Baltzer P, Hartenbach S, D'Andrea D, Helbich TH, Haug AR, Goldner GM, Wadsak W, Pfaff S, Mitterhauser M, Balber T, Berroteran-Infante N, Grahovac M, Babich J, Seitz C, Kramer G, Susani M, Mazal P, Kenner L, Shariat SF, Hacker M, Hartenbach M.

Clin Cancer Res. 2018 Dec 15;24(24):6300-6307. doi: 10.1158/1078-0432.CCR-18-0768. Epub 2018 Aug 23.

PMID:
30139879
33.

Breast ultrasound: recommendations for information to women and referring physicians by the European Society of Breast Imaging.

Evans A, Trimboli RM, Athanasiou A, Balleyguier C, Baltzer PA, Bick U, Camps Herrero J, Clauser P, Colin C, Cornford E, Fallenberg EM, Fuchsjaeger MH, Gilbert FJ, Helbich TH, Kinkel K, Heywang-Köbrunner SH, Kuhl CK, Mann RM, Martincich L, Panizza P, Pediconi F, Pijnappel RM, Pinker K, Zackrisson S, Forrai G, Sardanelli F; European Society of Breast Imaging (EUSOBI) , with language review by Europa Donna–The European Breast Cancer Coalition.

Insights Imaging. 2018 Aug;9(4):449-461. doi: 10.1007/s13244-018-0636-z. Epub 2018 Aug 9.

34.

The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study.

Poetter-Lang S, Staufer K, Baltzer P, Tamandl D, Muin D, Bastati N, Halilbasic E, Hodge JC, Trauner M, Kazemi-Shirazi L, Ba-Ssalamah A.

Eur Radiol. 2019 Feb;29(2):1048-1058. doi: 10.1007/s00330-018-5650-5. Epub 2018 Jul 27.

35.

Quantitative Apparent Diffusion Coefficient Derived From Diffusion-Weighted Imaging Has the Potential to Avoid Unnecessary MRI-Guided Biopsies of mpMRI-Detected PI-RADS 4 and 5 Lesions.

Polanec SH, Helbich TH, Bickel H, Wengert GJ, Pinker K, Spick C, Clauser P, Susani M, Shariat S, Baltzer PAT.

Invest Radiol. 2018 Dec;53(12):736-741. doi: 10.1097/RLI.0000000000000498.

PMID:
29985792
36.

Apparent diffusion coefficient values obtained by unenhanced MRI predicts disease-specific survival in bladder cancer.

Sevcenco S, Maj-Hes AB, Hruby S, Ponhold L, Heinz-Peer G, Rauchenwald M, Marszalek M, Klingler HC, Polanec S, Baltzer PAT.

Clin Radiol. 2018 Oct;73(10):881-885. doi: 10.1016/j.crad.2018.05.022. Epub 2018 Jun 30.

PMID:
29970242
37.

MRI-based quantification of residual fibroglandular tissue of the breast after conservative mastectomies.

Woitek R, Pfeiler G, Farr A, Kapetas P, Furtner J, Bernathova M, Schöpf V, Clauser P, Marino MA, Pinker K, Baltzer PA, Helbich TH.

Eur J Radiol. 2018 Jul;104:1-7. doi: 10.1016/j.ejrad.2018.04.028. Epub 2018 Apr 26.

PMID:
29857853
38.

Assessing the kidney function parameters glomerular filtration rate and effective renal plasma flow with dynamic FDG-PET/MRI in healthy subjects.

Geist BK, Baltzer P, Fueger B, Hamboeck M, Nakuz T, Papp L, Rasul S, Sundar LKS, Hacker M, Staudenherz A.

EJNMMI Res. 2018 May 9;8(1):37. doi: 10.1186/s13550-018-0389-1.

39.

Motion artifacts, lesion type, and parenchymal enhancement in breast MRI: what does really influence diagnostic accuracy?

Clauser P, Dietzel M, Weber M, Kaiser CG, Baltzer PA.

Acta Radiol. 2019 Jan;60(1):19-27. doi: 10.1177/0284185118770918. Epub 2018 Apr 18.

PMID:
29667880
40.

A Simple Ultrasound Based Classification Algorithm Allows Differentiation of Benign from Malignant Breast Lesions by Using Only Quantitative Parameters.

Kapetas P, Woitek R, Clauser P, Bernathova M, Pinker K, Helbich TH, Baltzer PA.

Mol Imaging Biol. 2018 Dec;20(6):1053-1060. doi: 10.1007/s11307-018-1187-x.

41.

Diffusion-Weighted Imaging With Apparent Diffusion Coefficient Mapping for Breast Cancer Detection as a Stand-Alone Parameter: Comparison With Dynamic Contrast-Enhanced and Multiparametric Magnetic Resonance Imaging.

Pinker K, Moy L, Sutton EJ, Mann RM, Weber M, Thakur SB, Jochelson MS, Bago-Horvath Z, Morris EA, Baltzer PA, Helbich TH.

Invest Radiol. 2018 Oct;53(10):587-595. doi: 10.1097/RLI.0000000000000465.

42.

How to use the Kaiser score as a clinical decision rule for diagnosis in multiparametric breast MRI: a pictorial essay.

Dietzel M, Baltzer PAT.

Insights Imaging. 2018 Jun;9(3):325-335. doi: 10.1007/s13244-018-0611-8. Epub 2018 Apr 3. Review.

43.

Virtual Touch IQ elastography reduces unnecessary breast biopsies by applying quantitative "rule-in" and "rule-out" threshold values.

Kapetas P, Clauser P, Woitek R, Pinker K, Bernathova M, Helbich TH, Baltzer PA.

Sci Rep. 2018 Feb 26;8(1):3583. doi: 10.1038/s41598-018-22065-7.

44.

The Assessment of Background Parenchymal Enhancement (BPE) in a High-Risk Population: What Causes BPE?

You C, Kaiser AK, Baltzer P, Krammer J, Gu Y, Peng W, Schönberg SO, Kaiser CG.

Transl Oncol. 2018 Apr;11(2):243-249. doi: 10.1016/j.tranon.2017.12.006. Epub 2018 Jan 28.

45.

3 Tesla breast MR imaging as a problem-solving tool: Diagnostic performance and incidental lesions.

Spick C, Szolar DHM, Preidler KW, Reittner P, Rauch K, Brader P, Tillich M, Baltzer PA.

PLoS One. 2018 Jan 2;13(1):e0190287. doi: 10.1371/journal.pone.0190287. eCollection 2018.

46.

MRI for the assessment of malignancy in BI-RADS 4 mammographic microcalcifications.

Bennani-Baiti B, Dietzel M, Baltzer PA.

PLoS One. 2017 Nov 30;12(11):e0188679. doi: 10.1371/journal.pone.0188679. eCollection 2017.

47.

Potential of Noncontrast Magnetic Resonance Imaging With Diffusion-Weighted Imaging in Characterization of Breast Lesions: Intraindividual Comparison With Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

Baltzer PAT, Bickel H, Spick C, Wengert G, Woitek R, Kapetas P, Clauser P, Helbich TH, Pinker K.

Invest Radiol. 2018 Apr;53(4):229-235. doi: 10.1097/RLI.0000000000000433.

PMID:
29190227
48.

Breast lesions classified as probably benign (BI-RADS 3) on magnetic resonance imaging: a systematic review and meta-analysis.

Spick C, Bickel H, Polanec SH, Baltzer PA.

Eur Radiol. 2018 May;28(5):1919-1928. doi: 10.1007/s00330-017-5127-y. Epub 2017 Nov 22. Review.

49.

A survey by the European Society of Breast Imaging on the utilisation of breast MRI in clinical practice.

Clauser P, Mann R, Athanasiou A, Prosch H, Pinker K, Dietzel M, Helbich TH, Fuchsjäger M, Camps-Herrero J, Sardanelli F, Forrai G, Baltzer PAT.

Eur Radiol. 2018 May;28(5):1909-1918. doi: 10.1007/s00330-017-5121-4. Epub 2017 Nov 22.

50.

Impact of hybrid PET/MR technology on multiparametric imaging and treatment response assessment of cervix cancer.

Daniel M, Andrzejewski P, Sturdza A, Majercakova K, Baltzer P, Pinker K, Wadsak W, Mitterhauser M, Pötter R, Georg P, Helbich T, Georg D.

Radiother Oncol. 2017 Dec;125(3):420-425. doi: 10.1016/j.radonc.2017.10.036. Epub 2017 Nov 15.

PMID:
29153465

Supplemental Content

Loading ...
Support Center